Sources

Every figure in Morning’s guides comes from a source listed here: FDA prescribing information, peer-reviewed trials and public health guidance. Each guide lists its own sources at the end; this page gathers them all.

How we choose and check them: Editorial policy.

GLP‑1 side effects, week by week

Nausea on a GLP‑1: why it happens and what helps

Constipation on a GLP‑1: causes, fixes, red flags

Diarrhea on GLP‑1s: how long it lasts and what helps

Sulfur burps, heartburn and reflux on GLP‑1s

Fatigue on a GLP‑1, and what helps

Hair loss on a GLP‑1: why it happens and what helps

WEGOVY (semaglutide) injection and tablets, prescribing information, revised 6/2026. DailyMed
ZEPBOUND (tirzepatide) injection, prescribing information, revised 8/2026. uspl.lilly.com
American Academy of Dermatology. Do you have hair shedding or hair loss? aad.org
American Academy of Dermatology. Hair loss: 18 causes. aad.org
US Food and Drug Administration. Biotin interference with troponin lab tests. fda.gov
DermNet. Telogen effluvium. dermnetnz.org
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf

Ozempic face: what it is and what actually helps

Sharma RK, et al. Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngology–Head and Neck Surgery, 2025;173(2):360–366. doi.org/10.1002/ohn.1209
Humphrey CD, Lawrence AC. Implications of Ozempic and other semaglutide medications for facial plastic surgeons. Facial Plastic Surgery, 2023;39(6):719–721. doi.org/10.1055/a-2148-6321
Lee KWA, et al. Ozempic face: an update and critical review. Journal of Cosmetic and Regenerative Medicine, 2026;1(1):19. doi.org/10.65381/jcrm.2026.01010019
Alam M, et al. Association of facial exercise with the appearance of aging. JAMA Dermatology, 2018;154(3):365–367. doi.org/10.1001/jamadermatol.2017.5142
WEGOVY (semaglutide) injection and tablets, prescribing information, revised 6/2026. DailyMed
ZEPBOUND (tirzepatide) injection, prescribing information, revised 8/2026. uspl.lilly.com
American Academy of Dermatology. 11 ways to reduce premature skin aging. aad.org
US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. odphp.health.gov
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf

Zepbound and Mounjaro side effects

Wegovy and Ozempic side effects, explained

How GLP‑1 medications work, in plain words

Your first month on a GLP‑1, week by week

Wegovy (semaglutide) injection and tablets, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
Ozempic (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
Zepbound (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed
Mounjaro (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed

GLP‑1 shot day: what to expect and what to eat

Wegovy (semaglutide) injection and tablets, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
Ozempic (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use. Novo Nordisk. DailyMed
Zepbound (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed
Mounjaro (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use. Eli Lilly. DailyMed

GLP‑1 injection sites and how to rotate them

Wegovy (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use (pen, prefilled syringe and FlexTouch). Novo Nordisk. DailyMed
Ozempic (semaglutide) injection, prescribing information, Medication Guide and Instructions for Use (pens and prefilled syringe). Novo Nordisk. DailyMed
Zepbound (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use (single-dose pen, vials and KwikPen). Eli Lilly. DailyMed
Mounjaro (tirzepatide) injection, prescribing information, Medication Guide and Instructions for Use (single-dose pen, vials and KwikPen). Eli Lilly. DailyMed

Weight-loss plateaus on a GLP‑1

Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 2022;28:2083–2091. doi.org/10.1038/s41591-022-02026-4
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. doi.org/10.1056/NEJMoa2032183
Tools for Practice #295. Summary of STEP 1, noting weight loss plateaued around week 60. College of Family Physicians of Canada, 2021. cfpclearn.ca
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387:205–216. doi.org/10.1056/NEJMoa2206038
Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clinical Obesity, 2025;15(3):e12734. doi.org/10.1111/cob.12734
Ard J, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes, Obesity and Metabolism, 2025;27(9):5064–5071. doi.org/10.1111/dom.16554
Orsama AL, et al. Weight rhythms: weight increases during weekends and decreases during weekdays. Obesity Facts, 2014;7(1):36–47. doi.org/10.1159/000356147
Polidori D, et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity, 2016. doi.org/10.1002/oby.21653
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Annals of Internal Medicine, 2010. pubmed.ncbi.nlm.nih.gov/20921542
US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. health.gov
Wegovy (semaglutide) prescribing information, FDA. DailyMed
Zepbound (tirzepatide) prescribing information, FDA. DailyMed

Semaglutide vs tirzepatide, side by side

Wegovy vs Ozempic, Zepbound vs Mounjaro

The Wegovy pill, explained

Traveling with a GLP‑1 pen: storage, TSA and shot day

Coming off a GLP‑1: how to keep the weight off

Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. doi.org/10.1111/dom.14725
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024;331(1):38-48. jamanetwork.com
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
Wegovy (semaglutide) prescribing information, FDA. DailyMed
Zepbound (tirzepatide) prescribing information, FDA. DailyMed

What to eat on a GLP‑1

Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122:344–367 (also published in Obesity). doi.org/10.1016/j.ajcnut.2025.04.023
The Obesity Society. Nutritional priorities to support GLP-1 therapy for obesity. obesity.org
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
American Academy of Family Physicians. Dietary Guidelines for 2025–2030: recommendations from the USDA and HHS. American Family Physician, 2026. aafp.org
National Academies. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. 2005. nap.nationalacademies.org
Wegovy (semaglutide) prescribing information, FDA. DailyMed
Zepbound (tirzepatide) prescribing information, FDA. DailyMed

A 7-day GLP‑1 meal plan

Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
Full text of the joint advisory, American Journal of Lifestyle Medicine, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12125019
US Department of Agriculture, Agricultural Research Service. FoodData Central (SR Legacy). fdc.nal.usda.gov
US Department of Agriculture. Leftovers and food safety. usda.gov
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf
Wegovy (semaglutide) prescribing information, FDA. DailyMed
Zepbound (tirzepatide) prescribing information, FDA. DailyMed

Food noise and GLP‑1 medicines

Hayashi D, et al. What is food noise? A conceptual model of food cue reactivity. Nutrients, 2023;15(22):4809. doi.org/10.3390/nu15224809
Dhurandhar EJ, et al. Food noise: definition, measurement, and future research directions. Nutrition & Diabetes, 2025;15:30. doi.org/10.1038/s41387-025-00382-x
Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity, 2025;33(2):289–297. doi.org/10.1002/oby.24216
Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 2021;23:754–762. doi.org/10.1111/dom.14280
Penn Medicine. Tirzepatide may only temporarily suppress brain activity involved in "food noise" (news release on a Nature Medicine case report), November 2025. newswise.com
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022;24(8):1553–1564. doi.org/10.1111/dom.14725
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA, 2024;331(1):38–48. jamanetwork.com
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Annals of Internal Medicine, 2010. pubmed.ncbi.nlm.nih.gov/20921542
Wegovy (semaglutide) prescribing information, FDA. DailyMed
Zepbound (tirzepatide) prescribing information, FDA. DailyMed

Alcohol on a GLP‑1: what to know before you drink

Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide. Novo Nordisk. DailyMed
Ozempic (semaglutide) injection, prescribing information and Medication Guide. Novo Nordisk. DailyMed
Zepbound (tirzepatide) injection, prescribing information and Medication Guide. Eli Lilly. DailyMed
Mounjaro (tirzepatide) injection, prescribing information and Medication Guide. Eli Lilly. DailyMed
Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2025;82(4):395-405. PubMed
American Diabetes Association. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2025. Diabetes Care 2025;48(Suppl 1). Diabetes Care
National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and Causes of Pancreatitis. NIDDK
National Institute on Alcohol Abuse and Alcoholism. What Is A Standard Drink? NIAAA
National Institute on Alcohol Abuse and Alcoholism. Hangovers. NIAAA
2020 Dietary Guidelines Advisory Committee. Scientific Report, Part D, Chapter 11: Alcoholic Beverages. DietaryGuidelines.gov

Muscle loss on a GLP‑1, and how to protect it

Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025;27(5):2720–2729. doi.org/10.1111/dom.16275
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. doi.org/10.1056/NEJMoa2032183
Wilding JPH, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. Journal of the Endocrine Society, 2021 (ENDO 2021 abstract). newswise.com
Tinsley GM, et al. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. SAGE Open Medical Case Reports, 2025;13. Summarizes the STEP 1 DXA figures. doi.org/10.1177/2050313X251388724
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. odphp.health.gov
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf

Exercise on a GLP‑1: where to start

US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition, 2018. Executive summary. odphp.health.gov
Office of Disease Prevention and Health Promotion. Top 10 things to know about the second edition of the Physical Activity Guidelines for Americans. odphp.health.gov
Centers for Disease Control and Prevention. Measuring physical activity intensity. cdc.gov
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
Full text of the joint advisory, American Journal of Lifestyle Medicine, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12125019
Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine, 2021;384:1719–1730. pubmed.ncbi.nlm.nih.gov/33951361
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025;27(5):2720–2729. doi.org/10.1111/dom.16275
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021;384:989–1002. doi.org/10.1056/NEJMoa2032183
Zepbound (tirzepatide) prescribing information, FDA. DailyMed
Wegovy (semaglutide) prescribing information, FDA. DailyMed

GLP‑1s in perimenopause and menopause

Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity, 2025;33:851–860. doi.org/10.1002/oby.24254
Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight, 2019;4(5):e124865. doi.org/10.1172/jci.insight.124865
Hurtado MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause, 2024;31(4):266–274. doi.org/10.1097/GME.0000000000002310
Castaneda R, et al. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study. The Lancet Obstetrics, Gynaecology & Women's Health, 2026;2(2):e118–e128. doi.org/10.1016/S3050-5038(25)00145-100145-1)
The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022;29(7):767–794. menopause.org
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. American Journal of Clinical Nutrition, 2025;122:344–367. doi.org/10.1016/j.ajcnut.2025.04.023
Zepbound (tirzepatide) prescribing information, Eli Lilly and Company. DailyMed
Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed
US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. odphp.health.gov
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf

GLP‑1s and PCOS: what the research shows

Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism, 2023;108(10):2447–2469. doi.org/10.1210/clinem/dgad463
Austregésilo de Athayde De Hollanda Morais B, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications, 2024;38:108834. doi.org/10.1016/j.jdiacomp.2024.108834
Goldberg A, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews, 2024;25:e13704. doi.org/10.1111/obr.13704
Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reproductive BioMedicine Online, 2019;39:332–342. doi.org/10.1016/j.rbmo.2019.04.017
Wegovy (semaglutide) prescribing information, Novo Nordisk. DailyMed
Ozempic (semaglutide) prescribing information, Novo Nordisk. DailyMed
Zepbound (tirzepatide) prescribing information, Eli Lilly and Company. DailyMed
Mounjaro (tirzepatide) prescribing information, Eli Lilly and Company. DailyMed
US Departments of Agriculture and Health and Human Services. Dietary Guidelines for Americans, 2025–2030. cdn.realfood.gov/DGA.pdf